16
diseases, presented by the American Academy of Neurology [Assessment of
plasmapheresis, 1996].
Indications for plasmapheresis, established by the American
Academy of Neurology
Disease
Settings
Guillain-Barr
é
syndrome, severe form
Defined
Chronic inflammatory demyelinating
polyneuropathy
Defined
Polyneuropathy with monoclonal
gammapathy the possible role played by:
IgG/IgA
IgM
Defined
In study
Myasthenia gravis: in preparation for
operations or stroke
Defined
Myasthenic syndrome of Lambert-Eaton
Use possible
Acquired neuromyotoniya
In study
Stiff-man syndrome
In study
Cryoglobulinemic polyneuropathy
In study
CNS damage during lupus
In study
Acute disseminated encephalomyelitis
In study
Multiple sclerosis
Use possible
In addition, in this analysis presented is data on value of plasmapheresis - from $
1,000 to $ 2,000 per treatment, and the rate of five such sessions can cost $ 5,000-
10,000. But, on the other hand, a course of intravenous immunoglobulin-therapy also
costs about $10,000.
These positions have not changed significantly later [Cortese I. et al., 2011].
Sources
Abele M., Weller M., Mescheriakov S. et al. Cerebellar ataxia with glutamic acid
decarboxylase autoantibodies // Neurology.
–
1999.
–
Vol. 52, № 4. –
P. 857-859.
Algahtani H., Moulin D.E., Bolton C.F., Abulaban A.A. Guillain-Barre syndrome
following cardiac surgery. Difficult diagnosis in the intensive care unit // Neurosciences
(Riyadh).
–
2009.
–
Vol. 14, №
4.
–
P. 374-378.
Allain J.-P. Emerging viruses in blood transfusion // Vox Sang. - 1998. - Vol. 74,
Suppl. 2. - P. 125-129.
17
Andrews P.I., Dicter M.A., Bercovic S.F. et al.
Plasmapheresis in Rasmussen’s
encephalitis // Neurology.
–
1995.
–
Vol. 46, № 1.
- P. 242-246.
Anlar B., Yimaz V., Saruhan-Direskeneli G. Long remission in muscle-specific
kinase antibody-positive juvenile myasthenia // Pediatr. Neurol.
–
2009.
–
Vol. 40, № 6.
–
P. 455-456.Applebee A., Panitch H. Early stege and ling term treatment of multiple
sclerosis with interferon-
β
// Biologics.
–
2009.
–
№ 3. –
P. 257-271.
Assessment of plasmapheresis. Report of the therapeutics and technology
assessment subcommittee of the AMERICAN Academy of neurology // Neurology.
–
1996.
–
Vol. 47, № 3. –
P. 840-843.
Batocchi A.P., Evoli A., Di Schino C., Tonali P. Therapeutic apheresis in myasthenia
gravis // Ther. Apher.
–
2000.
–
Vol. 4, № 4. –
P. 275-279.
Bell C., Graham J., Earnshaw S. et al. Cost-effectiveness of four immunomodulatory
therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term
clinical data // J. Manag. Care Pharm.
–
2007.
–
Vol. 13, № 3. –
P. 245-261.
Ben David Y., Warner E., Levitan M. et al. Autoimmune paraneoplastic cerebellar
degeneration in ovarian carcinoma patients treated with plasmapheresis // Cancer.
–
1996.
–
Vol. 78, № 10. –
P. 2153-2156.
Bernard C.C.A., Johns T.G., Slavin A. et al. Myelin oligodendrocyte glycoprotein: a
novel candidate autoantigen in multiple sclerosis // J. Mol. Med. - 1997. - Vo
l. 75, № 2.
-
P. 77-88.
Bonnan M., Valentino R., Olindo S. et al. Plasma exchange in severe spinal attacks
associated with neuromyelitis optica spectrum disorder // Mult. Scler.
–
2009.
–
Vol. 15,
№ 4. –
P. 487-492.
Bonnan M., Cabre P. Plasma exchange in severe attacks of neuromyelitis optica //
Mult. Scler. Int.
–
2012.
–
2012: 787630.
Brannagan Th.H., Nagle K.L., Lange D.J., Rowland L.P. Complications of
intravenous immune globulin treatment in neurologic disease // Neurology. - 1996. - Vol.
47, № 3.
- P. 674-677.
Brannagan T.H. Current treatments of chronic immune-mediated demyelinating
polyneuropathies // Muscle Nerve.
–
2009.
–
Vol. 39, № 5. –
P. 563-578.
Brashear H.R., Phillips L.H. Autoantibodies to GABAergic neurons and response to
plasmapheresis in stiff-man syndrome // Neurology. - 1991. -
Vol. 41, № 10.
- P. 1588-
1592.
Burwinkel M., Riemer C., Schwartz A. et al. Role of cytokines and chemokines in
prion infections of the central nervous system // Int. J. Dev. Neurosci.
–
2004.
–
Vol. 22,
№ 7. –
P. 497-505.
Buzzigoli S.B., Genovese M., Lambelet P. et al. Plasmapheresis treatment in
Gillain-Barr
é
syndrome: potential benefit over intravenous immunoglobulin // Anaesth.
Intensive Care.
–
2010.
–
Vol. 38, № 2. –
P. 387-389.